Compare Incyte Corporation (INCY) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs STMicroelectronics NV — how do they compare? Incyte Corporation trades at $120.64 (market cap $24.54B), while STMicroelectronics NV trades at $55.21 (market cap $49.21B). The key difference: STMicroelectronics NV is far larger — about 2× Incyte Corporation's market cap, and STMicroelectronics NV pays a 0.65% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | STM | |
|---|---|---|
Market Cap | $24.54B | $49.21B |
Sector | Health | Financials |
52-Week High | $129.93 | $79.91 |
52-Week Low | $81.61 | $21.20 |
Enterprise Value | $20.04B | $47.21B |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
STM's stock trades at $55.09, up 1.36% on the day, with a neutral technical signal and bearish moving average trend. The company reported Q2 2026 EPS of $0.31, beating expectations, but faces profitability challenges with a net margin of 3.56%. Recent news highlights strong AI data center growth potential, targeting over $2 billion in revenues by 2027. Cash flow improved in 2025 with net cash flow of $555 million.
The outlook is mixed; analyst consensus is bullish with a $74.63 price target, but high P/E of 107.92 indicates premium valuation. Key opportunities include AI and auto demand, while risks involve margin pressure and competitive threats. Execution on growth targets is critical for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
